Cyprium Therapeutics, a majority-owned subsidiary of Fortress Biotech, entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $205 million in gross proceeds at closing. The voucher was issued following the FDA approval of ZYCUBO on Jan. 12, 2026, and was transferred to Cyprium under its prior transaction with Sentynl Therapeutics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortress Biotech Inc. published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.